CRSP

CRISPR Therapeutics AG

55.70 USD
+0.65 (+1.18%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

CRISPR Therapeutics AG stock is down -21.64% since 30 days ago. The next earnings date is May 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 62.5% of the previous 7 April’s closed higher than March. In the last 10 Unusual Options Trades, there were 3 PUTs, 7 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
19 Apr 19:40 16 Jan, 2026 72.50 PUT 40 44
19 Apr 19:45 16 Jan, 2026 55.00 PUT 58 31
22 Apr 13:44 20 Sep, 2024 52.50 CALL 30 1
22 Apr 15:26 19 Jul, 2024 55.00 CALL 73 99
22 Apr 15:31 20 Sep, 2024 40.00 CALL 40 2
22 Apr 16:19 16 Jan, 2026 47.50 CALL 20 1
22 Apr 17:25 19 Jul, 2024 67.50 CALL 90 48
22 Apr 18:10 21 Jun, 2024 65.00 PUT 30 2817
22 Apr 18:38 17 May, 2024 60.00 CALL 100 1122
22 Apr 19:49 17 May, 2024 60.00 CALL 102 1122

About CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases. The company's lead product candidate is CTX001, an ex-viggered therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies.

  • Citigroup
    Thu Apr 18, 12:10
    buy
    confirm
  • Needham
    Thu Apr 11, 06:37
    buy
    confirm